Renal cell carcinoma
- 1 May 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 17 (3), 261-267
- https://doi.org/10.1097/01.cco.0000155007.51495.d6
Abstract
This review focuses on recent developments in the biology and clinical therapeutics of renal cell carcinoma. Given historically limited advances in this disease, a more thorough understanding and testing of rationally targeted agents is needed. Von Hippel-Lindau gene inactivation is observed in most clear cell renal carcinoma, driving the malignant phenotype. The resulting vascular endothelial growth factor overexpression has been targeted though various approaches, with a clear signal of anti-tumor activity. In addition, immunotherapy remains a therapeutic standard in renal cell carcinoma and an area of ongoing investigation. Observation of small renal masses may represent a viable clinical option. Renal cell carcinoma has become a model disease for rationally targeted therapeutics based on significant understanding of the underlying biology. Recent advances have increased the potential for meaningful improvements in clinical outcomes for renal cell carcinoma patients.Keywords
This publication has 38 references indexed in Scilit:
- Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma TherapyClinical Cancer Research, 2004
- Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromesCancer Cell, 2004
- Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinomaOncogene, 2004
- Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor GrowthPLoS Biology, 2003
- Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene RegulationMolecular and Cellular Biology, 2003
- TSC2 regulates VEGF through mTOR-dependent and -independent pathwaysCancer Cell, 2003
- The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysisNature, 1999
- Inactivation of the von Hippel–Lindau ( VHL ) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL ‐independent pathway in clear cell renal tumourigenesisGenes, Chromosomes and Cancer, 1998
- Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.Proceedings of the National Academy of Sciences, 1994
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994